WO2025055910 - USE OF PHARMACEUTICAL COMPOSITION IN PREPARATION OF DRUG FOR OSTEOPOROSIS
National phase entry is expected:
Publication Number
WO/2025/055910
Publication Date
20.03.2025
International Application No.
PCT/CN2024/118051
International Filing Date
10.09.2024
Title **
[English]
USE OF PHARMACEUTICAL COMPOSITION IN PREPARATION OF DRUG FOR OSTEOPOROSIS
[French]
UTILISATION D'UNE COMPOSITION PHARMACEUTIQUE DANS LA PRÉPARATION D'UN MÉDICAMENT CONTRE L'OSTÉOPOROSE
[Chinese]
一种药物组合物在制备骨质疏松药物中的应用
Applicants **
SUZHONG PHARMACEUTICAL GROUP CO., LTD.
JIANGSU SUZHONG PHARMACEUTICAL R & D INSTITUTE CO., LTD.
Inventors
TANG, Haitao
WANG, Fujiang
GE, Haitao
MA, Jimei
WANG, Dandan
WANG, Dianguang
Priority Data
202311195278.4
16.09.2023
CN
202311722277.0
14.12.2023
CN
202410625244.2
20.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2622 | |
| EPO | Filing, Examination, Granting | 18634 | |
| Japan | Filing, Examination, Granting | 2461 | |
| South Korea | Filing, Examination, Granting | 2867 | |
| USA | Filing, Examination, Granting | 7390 |
Total:
33,974
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the use of a pharmaceutical composition in the preparation of a drug for gout or osteoporosis, which belongs to the pharmaceutical field. The drug has significant effects with regard to preventing or treating gout or osteoporosis and relatively good safety.[French]
La présente invention concerne l'utilisation d'une composition pharmaceutique dans la préparation d'un médicament pour le traitement de la goutte ou de l'ostéoporose, ce qui relève du domaine pharmaceutique. Le médicament présente des effets significatifs en ce qui concerne la prévention ou le traitement de la goutte ou de l'ostéoporose et une sécurité relativement bonne.[Chinese]
本发明涉及一种药物组合物在制备痛风或骨质疏松的药物中的应用，属于制药领域，具有明显的预防或治疗痛风或骨质疏松的作用及较好的安全性。